Novel phage Lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter Baumannii in a mouse bacteremia model

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 1983-1991

  Lood, Rolf ^a   Winer, Benjamin Y ^a,d   Pelzek, Adam J ^a,e   Diez Martinez, Roberto ^a,b   Thandar, Mya ^a   Euler, Chad W ^a,c   Schuch, Raymond ^a,f   Fischetti, Vincent A ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c CITY UNIVERSITY OF NEW YORK   (United States)

^d Lewis Thomas Laboratory   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f ContraFect Corp ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL ENZYME; LYSIN; PLYF 301; PLYF 303; PLYF 306; PLYF 307; PLYF 309; PLYF 311; PLYF 315; PLYF 320; PLYF 321; PLYF 324; PLYF 328; PLYF 330; PLYF 332; PLYF 334; PLYF 336; PLYF 338; PLYF 340; PLYF 344; PLYF 347; PLYF 351; PLYF 376; UNCLASSIFIED DRUG; LYSOZYME;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOLYSIS; BACTERIUM ISOLATE; BIOFILM; CONTROLLED STUDY; FEMALE; GENE LIBRARY; GENETIC CODE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHAGE; ACINETOBACTER INFECTIONS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; SEPSIS;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; BIOFILMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MURAMIDASE; SEPSIS;

EID: 84928910762     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04641-14     Document Type: Article

References (33)

1. Seifert H, Dijkshoorn L, Gerner-Smidt P, Pelzer N, Tjernberg I, Vaneechoutte M. 1997. Distribution of Acinetobacter species on human skin: comparison of phenotypic and genotypic identification methods. J Clin Microbiol 35:2819-2825.
2. Visca P, Seifert H, Towner KJ. 2011. Acinetobacter infection: an emerging threat to human health. IUBMB Life 63:1048-1054. http://dx.doi.org/10.1002/iub.534.
3. Karageorgopoulos DE, Falagas ME. 2008. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 8:751-762. http://dx.doi.org/10.1016/S1473-3099(08)70279-2.
4. Murray CK, Roop SA, Hospenthal DR, Dooley DP, Wenner K, Hammock J, Taufen N, Gourdine E. 2006. Bacteriology of war wounds at the time of injury. Mil Med 171:826-829.
5. García-Quintanilla M, Pulido MR, López-Rojas R, Pachón J, McConnell MJ. 2013. Emerging therapies for multidrug resistant Acinetobacter baumannii. Trends Microbiol 21:157-163. http://dx.doi.org/10.1016/j.tim.2012.12.002.
6. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309-317. http://dx.doi.org/10.1086/421946.
7. Livermore DM. 2009. Has the era of untreatable infections arrived? J Antimicrob Chemother 64(Suppl 1):i29-i36. http://dx.doi.org/10.1093/jac/dkp255.
8. Lee K, Yong D, Jeong SH, Chong Y. 2011. Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei Med J 52:879-891. http://dx.doi.org/10.3349/ymj.2011.52.6.879.
9. Cerqueira GM, Peleg AY. 2011. Insights into Acinetobacter baumannii pathogenicity. IUBMB Life 63:1055-1060. http://dx.doi.org/10.1002/iub.533.
10. Wendt C, Dietze B, Dietz E, Rüden H. 1997. Survival of Acinetobacter baumannii on dry surfaces. J Clin Microbiol 35:1394-1397.
11. Poirel L, Bonnin RA, Nordmann P. 2011. Genetic basis of antibiotic resistance in pathogenic Acinetobacter species. IUBMB Life 63:1061-1067. http://dx.doi.org/10.1002/iub.532.
12. Gayoso CM, Mateos J, Méndez JA, Fernández-Puente P, Rumbo C, Tomás M, Martínez de Ilarduya O, Bou G. 2014. Molecular mechanisms involved in the response to desiccation stress and persistence in Acinetobacter baumannii. J Proteome Res 13:460-476. http://dx.doi.org/10.1021/pr400603f.
13. Pastagia M, Schuch R, Fischetti VA, Huang DB. 2013. Lysins: the arrival of pathogen-directed anti-infectives. J Med Microbiol 62:1506-1516. http://dx.doi.org/10.1099/jmm.0.061028-0.
14. Lukacik P, Barnard TJ, Keller PW, Chaturvedi KS, Seddiki N, Fairman JW, Noinaj N, Kirby TL, Henderson JP, Steven AC, Hinnebusch BJ, Buchanan SK. 2012. Structural engineering of a phage lysin that targets Gram-negative pathogens. Proc Natl Acad Sci U S A 109:9857-9862. http://dx.doi.org/10.1073/pnas.1203472109.
15. Lood R, Raz A, Molina H, Euler CW, Fischetti VA. 2014. A highly active and negatively charged Streptococcus pyogenes lysin with a rare D-alanyl-Lalanine endopeptidase activity protects mice against streptococcal bacteremia. Antimicrob Agents Chemother 58:3073-3084. http://dx.doi.org/10.1128/AAC.00115-14.
16. Schuch R, Nelson D, Fischetti VA. 2002. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418:884-889. http://dx.doi.org/10.1038/nature01026.
17. Loeffler JM, Nelson D, Fischetti VA. 2001. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294:2170-2172. http://dx.doi.org/10.1126/science.1066869.
18. Gilmer DB, Schmitz JE, Euler CW, Fischetti VA. 2013. Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 57:2743-2750. http://dx.doi.org/10.1128/AAC.02526-12.
19. Lai M-J, Lin N-T, Hu A, Soo P-C, Chen L-K, Chen L-H, Chang K-C. 2011. Antibacterial activity of Acinetobacter baumannii phage-AB2 endolysin (LysAB2) against both Gram-positive and Gram-negative bacteria. Appl Microbiol Biotechnol 90:529-539. http://dx.doi.org/10.1007/s00253-011-3104-y.
20. Díez-Martínez R, de Paz H, Bustamante N, García E, Menéndez M, García P. 2013. Improving the lethal effect of Cpl-7, a pneumococcal phage lysozyme with broad bactericidal activity, by inverting the net charge of its cell wall-binding module. Antimicrob Agents Chemother 57:5355-5365. http://dx.doi.org/10.1128/AAC.01372-13.
21. Walmagh M, Briers Y, dos Santos SB, Azeredo J, Lavigne R. 2012. Characterization of modular bacteriophage endolysins from Myoviridae phages OBP, 201-2-1 and PVP-SE1. PLoS One 7:e36991. http://dx.doi.org/10.1371/journal.pone.0036991.
22. Briers Y, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, Aertsen A, Oliveira H, Azeredo J, Verween G, Pirnay J-P, Miller S, Volckaert G, Lavigne R. 2014. Engineered endolysin-based "artilysins" to combat multidrug-resistant Gram-negative pathogens. mBio 5(4): e01379-14. http://dx.doi.org/10.1128/mBio.01379-14.
23. Schmitz JE, Daniel A, Collin M, Schuch R, Fischetti VA. 2008. Rapid DNA library construction for functional genomic and metagenomic screening. Appl Environ Microbiol 74:1649-1652. http://dx.doi.org/10.1128/AEM.01864-07.
24. Hare JM, Ferrell JC, Witkowski TA, Grice AN. 2014. Prophage induction and differential RecA and UmuDAb transcriptome regulation in the DNA damage responses of Acinetobacter baumannii and Acinetobacter baylyi. PLoS One 9:e93861. http://dx.doi.org/10.1371/journal.pone.0093861.
25. Snitkin ES, Zelazny AM, Montero CI, Stock F, Mijares L, NISC Comparative Sequence Program, Murray PR, Segre JA. 2011. Genome-wide recombination drives diversification of epidemic strains of Acinetobacter baumannii. Proc Natl Acad Sci U S A 108:13758-13763. http://dx.doi.org/10.1073/pnas.1104404108.
26. Oechslin F, Daraspe J, Giddey M, Moreillon P, Resch G. 2013. In vitro characterization of PlySK1249, a novel phage lysin, and assessment of its antibacterial activity in a mouse model of Streptococcus agalactiae bacteremia. Antimicrob Agents Chemother 57:6276-6283. http://dx.doi.org/10.1128/AAC.01701-13.
27. Obeidat N, Jawdat F, Al-Bakri AG, Shehabi AA. 2014. Major biologic characteristics of Acinetobacter baumannii isolates from hospital environmental and patients' respiratory tract sources. Am J Infect Control 42: 401-404. http://dx.doi.org/10.1016/j.ajic.2013.10.010.
28. Fischetti VA. 2011. Exploiting what phage have evolved to control Grampositive pathogens. Bacteriophage 1:188-194. http://dx.doi.org/10.4161/bact.1.4.17747.
29. Payne KM, Hatfull GF. 2012. Mycobacteriophage endolysins: diverse and modular enzymes with multiple catalytic activities. PLoS One 7:e34052. http://dx.doi.org/10.1371/journal.pone.0034052.
30. Saleem F, Ahmad S, Yaqoob Z, Rasool SA. 2009. Comparative study of two bacteriocins produced by representative indigenous soil bacteria. Pak J Pharm Sci 22:252-258.
31. Hibbing ME, Fuqua C, Parsek MR, Peterson SB. 2010. Bacterial competition: surviving and thriving in the microbial jungle. Nat Rev Microbiol 8:15-25. http://dx.doi.org/10.1038/nrmicro2259.
32. Hughes KA, Sutherland IW, Clark J, Jones MV. 1998. Bacteriophage and associated polysaccharide depolymerases: novel tools for study of bacterial biofilms. J Appl Microbiol 85:583-590. http://dx.doi.org/10.1046/j.1365-2672.1998.853541.x.
33. Longo F, Vuotto C, Donelli G. 2014. Biofilm formation in Acinetobacter baumannii. New Microbiol 37:119-127.